(Reuters) -Pfizer has obtained early U.S. antitrust clearance greater than every week early for its proposed $7.3 billion Metsera acquisition, which has been known as into query by Novo Nordisk’s greater $8.5 billion provide.
Metsera has declared Novo’s provide superior, and given Pfizer till Tuesday to boost its bid.
The U.S. Federal Commerce Fee granted early termination of the ready interval required beneath the Hart-Scott-Rodino Act, which governs antitrust opinions. The ready interval was initially set to run out on November 7, Pfizer mentioned on Friday.
The clearance means Pfizer might transfer forward with its proposed buy of Metsera with out additional antitrust evaluate from U.S. regulators. Metsera shareholders are at the moment resulting from vote on the deal on November 13.
Pfizer mentioned Danish drugmaker Novo was an organization with a dominant market place making an attempt to suppress competitors in violation of regulation by taking up an rising American challenger within the fast-growing weight problems drug market. Pfizer known as the bid “reckless” and mentioned it was structured to bypass regulatory scrutiny.
Novo Nordisk, the maker of Wegovy and Ozempic, supplied as much as $8.5 billion for Metsera, together with $6 billion upfront.
Pfizer’s deal for Metsera is a part of its push to enter the $150 billion weight problems drug market, because it seems to be to offset falling COVID-19-related revenues and looming patent expirations. The corporate has confronted setbacks in growing its personal weight-loss therapies and doesn’t promote one.
(Reporting by Kamal Choudhury, Christy Santhosh and Siddhi Mahatole in Bengaluru; Modifying by Shilpi Majumdar)
